Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICROLITE vs CALCIUM GLUCONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MICROLITE (lithium citrate) is not a standard drug; no specific mechanism available. Assuming a hypothetical electrolyte supplement, it would act by replacing essential electrolytes.
Calcium gluconate dissociates to provide calcium ions, which are essential for nerve impulse transmission, muscle contraction, cardiac function, and blood coagulation. It acts as a mineral electrolyte replenisher.
Electrolyte replenishment,Hypokalemia,Hypomagnesemia
Emergency treatment of hypocalcemia,Cardiac resuscitation (e.g., hyperkalemia, calcium channel blocker overdose, beta-blocker overdose),Treatment of hypermagnesemia,Treatment of acute symptomatic hypocalcemic tetany,Off-label: Prevention of hypocalcemia during massive blood transfusion, adjunctive treatment of lead poisoning (calcium EDTA), and treatment of fluoride poisoning
1 tablet orally every 8 hours with or without food.
Intravenous: 1-2 grams (10-20 m L of 10% solution) administered slowly over 5-10 minutes. May repeat based on serum calcium levels.
Terminal elimination half-life is 12–15 hours in healthy adults, allowing twice-daily dosing. Half-life may be prolonged in renal impairment (up to 30 hours in severe cases).
Rapid distribution half-life ~5-10 min; terminal half-life 3-6 hours due to redistribution and renal excretion; clinically, effect duration is short (1-2 hours) due to rapid redistribution into bone and other tissues.
Not metabolized; excreted unchanged by kidneys.
Calcium gluconate is not metabolized. It dissociates to release calcium ions, which are distributed in the body and excreted primarily via the kidneys. The gluconate moiety is metabolized via the Krebs cycle.
Renal excretion accounts for approximately 70% of the dose, primarily as unchanged drug. Fecal elimination constitutes about 30%, with a minor contribution from biliary excretion (<10%).
Primarily renal (calcium is filtered and reabsorbed); negligible biliary/fecal. >98% of body calcium is in bone; excretion is complex and homeostatically regulated.
98% bound to serum albumin. Minimal binding to alpha-1-acid glycoprotein.
Approximately 45% bound to albumin; remaining free ionized calcium is the active form.
0.15–0.20 L/kg, indicating distribution primarily into extracellular fluid. Does not extensively penetrate tissues or cross the blood-brain barrier significantly.
0.6-1.0 L/kg (distributes into extracellular fluid and bone; increases with bone turnover).
Oral: 90% (well absorbed, minimal first-pass metabolism). Intramuscular: 100% (complete absorption).
IV: 100%; IM: poor and erratic (not recommended); oral: ~20-30% (limited by absorption and binding, not used for urgent hypocalcemia).
GFR 30-50 m L/min: 1 tablet every 12 hours; GFR 15-29 m L/min: 1 tablet every 24 hours; GFR <15 m L/min: contraindicated.
No specific dose adjustment for renal impairment; however, caution in severe renal failure (GFR <30 m L/min) due to risk of hypercalcemia. Monitor serum calcium closely.
Child-Pugh A: no adjustment; Child-Pugh B: 1 tablet every 12 hours; Child-Pugh C: contraindicated.
No adjustment required for hepatic impairment.
Weight <30 kg: 10 mg/kg/dose orally every 8 hours; Weight ≥30 kg: same as adult dosing.
Neonates and infants: 100-200 mg/kg/dose (1-2 m L/kg of 10% solution) IV slowly, maximum 2 g; children: 1-2 g/dose IV, maximum 2 g. Dilute to 50 mg/m L (5% solution) for IV administration.
No specific dose adjustment required based on age alone; monitor renal function and adjust per renal adjustment guidelines.
Start at lower end of dosing range (e.g., 1 gram IV) due to increased risk of hypercalcemia and potential underlying renal insufficiency. Monitor calcium levels and cardiac function.
None
No FDA black box warning.
Use with caution in renal impairment; monitor serum electrolytes; avoid in patients with hyperkalemia or hypermagnesemia.
Risk of hypercalcemia; monitor serum calcium levels closely during therapy.,Risk of cardiac arrhythmias, especially if administered too rapidly or in patients receiving digoxin.,Avoid extravasation; may cause severe tissue necrosis (treat with hyaluronidase).,Use caution in renal impairment, sarcoidosis, or history of renal calculi.,Concomitant use with thiazide diuretics may increase risk of hypercalcemia.
Hyperkalemia, hypermagnesemia, severe renal impairment.
Hypercalcemia,Severe renal failure (relative, use with caution),Patients with ventricular fibrillation (use during cardiopulmonary resuscitation may be indicated),Digoxin toxicity (relative; may exacerbate arrhythmias, use with extreme caution)
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes) unless monitored. Salt substitutes (e.g., KCl) increase hyperkalemia risk. Take with food to minimize GI upset.
Avoid high-calcium foods (dairy, fortified cereals) if hypercalcemia is a concern; oxalate-rich foods (spinach, rhubarb) may reduce absorption; do not take within 2 hours of iron or tetracycline antibiotics.
MICROLITE (magnesium citrate) is generally considered low risk for teratogenicity. No increased risk of major malformations has been reported in human studies. First trimester: No specific data but theoretical risk minimal due to poor oral absorption. Second/Third trimester: No known adverse fetal effects; used therapeutically for preeclampsia prevention at higher doses (IV magnesium sulfate, not this oral form).
FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies not available. Second/third trimesters: Calcium gluconate is a physiologic electrolyte; deficiency may cause fetal skeletal abnormalities, but supplementation at recommended doses is unlikely to increase risk of major malformations. High doses may cause maternal hypercalcemia; risk of fetal hypoparathyroidism, tetany, and seizures if maternal calcium acutely increased. No known teratogenicity.
Magnesium is excreted into breast milk; however, oral magnesium citrate is poorly absorbed. Infant exposure is likely minimal. M/P ratio not established. Use caution with high doses as diarrhea in mother may occur, but breastfeeding is generally considered compatible.
Excreted into breast milk; M/P ratio approximately 0.5. Considered compatible with breastfeeding in usual maternal doses. Monitor infant for signs of hypercalcemia if maternal doses are high.
No dosage adjustment typically required for oral magnesium citrate during pregnancy. However, gastrointestinal absorption may be slightly decreased; no change recommended. Avoid high doses due to risk of maternal diarrhea and electrolyte imbalance.
Pregnancy-induced physiologic changes (increased plasma volume, increased GFR, placental calcium transfer) may lower maternal calcium levels; monitor and adjust dose as needed to maintain normal serum calcium. Intravenous doses typically require similar mg/kg dosing as non-pregnant; oral dosing may require a slight increase (10-20%) to compensate for increased demands and excretion. No standardized adjustment; individualized based on serum calcium levels.
Microlite is a potassium-magnesium supplement used for electrolyte repletion. Monitor renal function prior to initiation; avoid in severe renal impairment (Cr Cl <30 m L/min). Use cautiously with ACE inhibitors, ARBs, or potassium-sparing diuretics due to hyperkalemia risk. Infuse slowly if intravenous to avoid phlebitis.
Administer via slow IV push (1-2 m L/min) to avoid cardiac arrest; monitor ECG during infusion; do not mix with bicarbonate or phosphate solutions; extravasation causes tissue necrosis; use with caution in digitalis toxicity.
Take with food or after meals to reduce gastrointestinal irritation.,Do not crush or chew extended-release tablets; swallow whole.,Report muscle weakness, fatigue, or irregular heartbeat immediately.,Avoid salt substitutes containing potassium unless directed by your healthcare provider.,Store at room temperature away from moisture and heat.
Report any pain, redness, or swelling at injection site immediately,Avoid taking calcium supplements or antacids containing calcium without consulting your doctor,Inform about any heart conditions, especially irregular heartbeat,May cause dizziness or fainting if infused too quickly
No interactions on record
"Calcium gluconate provides exogenous calcium, which can counteract the calcium channel blocking effect of nimodipine. This reduces nimodipine's ability to inhibit calcium influx into vascular smooth muscle cells, potentially decreasing its antihypertensive and vasodilatory efficacy. Clinically, coadministration may lead to reduced nimodipine effectiveness in preventing cerebral vasospasm after subarachnoid hemorrhage."
"Sodium glycerophosphate, an organic phosphate source, can chelate calcium ions in the gastrointestinal tract, forming insoluble calcium phosphate complexes. This reduces the absorption of orally administered calcium gluconate, leading to lower serum calcium concentrations. Clinically, this may result in diminished efficacy of calcium supplementation, potentially exacerbating hypocalcemia in susceptible patients."
"Calcium gluconate chelates deferiprone in the gastrointestinal tract, forming a non-absorbable complex that reduces deferiprone's bioavailability. This results in decreased serum concentrations and diminished therapeutic efficacy of deferiprone, potentially leading to inadequate chelation of iron in patients with iron overload. Clinically, patients may experience suboptimal reduction of serum ferritin and increased risk of iron-related organ damage."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICROLITE vs CALCIUM GLUCONATE, answered by our medical review team.
MICROLITE is a Electrolyte Supplement that works by MICROLITE (lithium citrate) is not a standard drug; no specific mechanism available. Assuming a hypothetical electrolyte supplement, it would act by replacing essential electrolytes.. CALCIUM GLUCONATE is a Electrolyte Supplement that works by Calcium gluconate dissociates to provide calcium ions, which are essential for nerve impulse transmission, muscle contraction, cardiac function, and blood coagulation. It acts as a mineral electrolyte replenisher.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICROLITE and CALCIUM GLUCONATE depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICROLITE is: 1 tablet orally every 8 hours with or without food.. The standard adult dose of CALCIUM GLUCONATE is: Intravenous: 1-2 grams (10-20 m L of 10% solution) administered slowly over 5-10 minutes. May repeat based on serum calcium levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICROLITE and CALCIUM GLUCONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICROLITE is classified as Category C. MICROLITE (magnesium citrate) is generally considered low risk for teratogenicity. No increased risk of major malformations has been reported in human studies. First trimester: No . CALCIUM GLUCONATE is classified as Category C. FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies not available. Second/third trimesters: Calcium gluconate is a physiologic electrolyte; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.